Home / Themes / GLP-1 Long '24: Pharma
GLP-1 Long '24: Pharma
Last updated
Theme thesis · 3/5 sections · Tickers 1 with notes · 2 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsThe current thesis for the GLP-1 '24: Pharma subtheme is mixed, focusing on the potential growth opportunities for SKYE and CRBP within the competitive landscap
Thesis
The current thesis for the GLP-1 '24: Pharma subtheme is mixed, focusing on the potential growth opportunities for SKYE and CRBP within the competitive landscape of GLP-1 drugs. While there is optimism about their ability to carve a niche in the expanding market for obesity and diabetes treatments, challenges remain regarding their capacity to compete with established players like LLY and NVO. The market dynamics are influenced by regulatory considerations, manufacturing capabilities, and the evolving competitive landscape.
Bull case
SKYE and CRBP are exploring innovative formulations that could enhance the efficacy and delivery of GLP-1 treatments, potentially differentiating them from larger competitors.
There is a growing demand for obesity and diabetes treatments, driven by increasing prevalence rates, which could provide a substantial market opportunity for new entrants.
Regulatory advancements and expedited approval processes for novel drugs could accelerate the time-to-market for SKYE and CRBP's products.
Bear case
Established players like LLY and NVO dominate the market with strong brand recognition and extensive distribution networks, posing a significant competitive threat to SKYE and CRBP.
Manufacturing and scaling up production processes remain challenging for smaller companies, potentially limiting SKYE and CRBP's ability to meet market demand.
The competitive landscape is rapidly evolving with numerous companies pursuing similar GLP-1 pathways, increasing the risk of market saturation and price competition.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| Competitive Market Share Analysis | Bi-Annually | Provides insights into SKYE and CRBP's positioning relative to competitors like LLY and NVO. | Google_Sheets |
| Prescription Volume Growth for GLP-1 Drugs | Monthly | Indicates market demand and adoption rates for SKYE and CRBP's products. | Google_Sheets |
| Regulatory Approval Timelines | Quarterly | Tracks the progress and speed of SKYE and CRBP's drug approval processes. | Google_Sheets |
Upcoming Catalysts
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| ABBV_ac706a0a | US submission is planned for the second quarter | 2026-04-01 | 2026-06-30 | US regulatory submission for RINVOQ in alopecia areata. | This is a critical step towards potential US market entry for RINVOQ in alopecia areata, a significant dermatological condition. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_171a2b75 | Over the course of 2026 | 2026-04-26 | 2026-12-31 | Readout of Phase 3 data for both RINVOQ and lutekizumab in hidradenitis suppurativa. | Positive data could lead to new indications for RINVOQ and establish lutekizumab as a lead asset, significantly expanding AbbVie's immunology franchise. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_1bed7b86 | This year | 2026-04-26 | 2026-12-31 | Data from the Crohn's disease platform study evaluating SKYRIZI in combination with ABBV 3A2 and lutekizumab. | This data could demonstrate superior efficacy for patients, strengthening SKYRIZI's position and AbbVie's overall IBD portfolio, especially for patients who have already received SKYRIZI. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_dfdda14f | anticipate seeing efficacy results later this year | 2026-04-26 | 2026-12-31 | Efficacy results from dose escalation studies for ABBV 619, an in vivo CD19 CAR T platform for autoimmune diseases. | Positive results could signal a transformative new approach to autoimmune diseases, offering deep and durable remission and a significant long-term growth driver. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_5d3fb65c | initiating a phase three study this year | 2026-04-26 | 2026-12-31 | Initiation of a Phase 3 study for tmAbA in an all-comers population in combination with bevacizumab for colorectal cancer. | This advances tmAbA into late-stage development for a multibillion-dollar opportunity in CRC, bolstering AbbVie's oncology pipeline. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_327b8be4 | data is expected around the middle of this year. | 2026-05-01 | 2026-06-30 | Phase 2 study data readout for ABBV 932 in bipolar depression. | Positive data could position ABBV 932 as a next-generation asset in psychiatry, potentially contributing to the replacement of Vraylar at its LOE in 2030. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_cba492a1 | an approval decision is expected this year. | 2026-04-26 | 2026-12-31 | US regulatory approval decision for Trenebody, a rapid-onset short-acting toxin for aesthetics. | Approval and subsequent launch could stimulate the aesthetics market by attracting new patients and ultimately accrue to Botox share, increasing overall revenue. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_80210779 | we will shortly see a readout over a head-to-head study with Entyvio. | 2026-04-26 | 2026-06-30 | Readout of head-to-head study data for SKYRIZI versus Entyvio in ulcerative colitis. | Positive data could provide a significant opportunity to continue SKYRIZI's momentum and leadership in the IBD market, differentiating it from other competitors. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_800b4101 | an approval decision is anticipated in the third quarter for tevapadon in Parkinson's disease. | 2026-07-01 | 2026-09-30 | US commercial approval decision for tevapadon in Parkinson's disease. | Approval would add a new, potentially multibillion-dollar asset to AbbVie's neuroscience portfolio, offering a new treatment option for Parkinson's disease. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_47f622ef | data from both trials expected in the second half of this year. | 2026-07-01 | 2026-12-31 | Data readout from Phase 3 studies evaluating QLIPTA and UBRELVY for menstrual migraine prevention. | Positive data could lead to label expansions for these leading migraine products, addressing a distinct and difficult-to-treat subtype of migraine and further driving sales. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_ced91140 | by Q3 or so | 2026-07-01 | 2026-09-30 | Data from two additional cohorts of a Phase 2 study evaluating bradicilacin in major depressive disorder (MDD). | This data will inform the development strategy and Phase 3 plans, with bradicilacin having the potential to be a groundbreaking new treatment in depression due to its strong efficacy and short-acting profile. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_c5da1469 | anticipated in the fourth quarter | 2026-10-01 | 2026-12-31 | US regulatory approval decision for RINVOQ in nonsegmental vitiligo. | Approval would expand RINVOQ's market to a new systemic indication, potentially adding to its multi-billion dollar sales trajectory. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
Constituents
- ABBVT3— AbbVie Inc.
- CRBPT3· no notes yet
- SKYET3· no notes yet